Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 01)
Citalopram Tablet
Product Images NDC 50090-5170
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Citalopram (NDC 50090-5170). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 02)
Table 1 shows the drug-placebo difference in the number of suicides per 1000 patients treated in different age ranges. In patients under 18 years old, there were 14 additional cases compared to placebo, while in patients aged 18-24, there were 1624 additional cases. However, in patients aged 25 and older, the drug was associated with a decrease in the number of suicides compared to placebo, with a reduction of 564 and 265.6 fewer cases per 1000 patients treated, respectively.*
Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 03)
Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 04)
The text appears to be a table presenting the percentage of patients discontinuing treatment due to adverse events in short-term, placebo-controlled depression trials of Citalopram and Placebo. The table lists various adverse events associated with discontinuation, including asthenia, gastrointestinal disorders like nausea and vomiting, dry mouth, central and peripheral nervous system disorders like dizziness, and psychiatric disorders like insomnia, somnolence, and agitation.*
Label Image (Lbl500905170)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
